JHVEPhoto/iStock Editorial via Getty Images
Amgen (NASDAQ:AMGN) shares fell in the evening hours on Tuesday after Cantor Fitzgerald argued that a potential loss of bone mineral density could be a safety risk linked to its obesity candidate MariTide (AMG-133).
According to investors and analysts, the experimental
